In the past year, the headlines about the FDA and GLP-1 medication may have seemed confusing. You may be asking yourself, “Are there changes to my medication?” “Do I have to stop taking my weight loss medication?” “Are compounded GLP-1s still safe?”
If you use compounded semaglutide or compounded tirzepatide, these FDA announcements may worry you.
Let’s break down how recent FDA announcements impact compounded GLP-1 medications, with dates, distinctions, and plain-English explanations.
Questions about compounded GLP-1 medication? Reach out to your care team.
The FDA took a series of targeted actions between late 2024 and early 2026. Here is a brief timeline of FDA announcements and actions that impact compounded GLP-1 medications:
Which of these actions are particularly important for someone on a compounded GLP-1 medication? The May 2025 deadline that affected 503B outsourcing facilities—large-scale bulk producers—stands out to us. This deadline did not apply to 503A pharmacies, which compound for individual patients with valid prescriptions.
There are 2 categories of compounding pharmacy in the US—503B outsourcing facilities and 503A pharmacies. They operate under different sections of federal law, have different legal authority, and the FDA's actions affected them differently.
These are large-scale operations that produce compounded medications in bulk and distribute them to medical practices and pharmacies across the country. Under federal law, they can only compound certain medications if they meet one of two criteria: either they’re on the 503B Bulk Drug Substances List, or the medications are on the FDA's active drug shortage list.
When the shortage ends, their legal authority to compound those specific medications also ends. This is the category most affected by the FDA's recent actions related to compounded GLP-1s. The grace periods that ended in May 2025 applied to 503B facilities.
These pharmacies compound medications for individual patients, one prescription at a time, based on a valid prescription from a licensed healthcare provider. They operate under Section 503A of the Federal Food, Drug, and Cosmetic Act.
503A pharmacies are not limited to drug shortage situations in the same way 503B pharmacies often are. 503A pharmacies are regulated primarily by state pharmacy boards, and requirements vary state by state.
503A pharmacies must follow USP standards set by the US Pharmacopeia, an independent scientific organization that establishes benchmarks for medication quality, purity, and safety.
Unlike 503B facilities, 503A facilities are not required to register with the FDA.
When the drug shortage ended, 503B bulk compounders lost their legal basis for GLP-1 compounding. But 503A pharmacies, which compound for individual patients with valid prescriptions, continued to operate legally under a different authority.
The FDA’s announcements—and headlines—could be misunderstood as applying to all compounding. They do not. Many of these regulation changes only affect 503B outsourcing facilities.
The FDA's February 2026 enforcement announcement specifically targeted companies selling products that:
What the February 2026 enforcement announcement was NOT targeting:
After the GLP-1 drug shortage was resolved, compounded GLP-1 medication from 503A pharmacies remained legal under the following conditions:
The FDA's April 2026 clarification explicitly reminded compounders of the conditions under which 503A pharmacies can continue to operate. This was a clarification of existing rules, not a ban.
CareBox works with state-licensed 503A pharmacies. Start your GLP-1 consultation today.
No, customers on compounded semaglutide and compounded tirzepatide through CareBox are not impacted by these enforcements. CareBox works with state-licensed 503A pharmacies. Here is what that means in practice:
The FDA's April 30, 2026 proposal affects 503B outsourcing facilities, not 503A pharmacies. As of May 2026, this proposal is in a public comment period through June 29, 2026. No final rule has been issued.
The FDA's actions to date have not stopped 503A pharmacy compounding of semaglutide. What ended was the broad authorization for 503B bulk compounders, which relied on the drug shortage designation. 503A pharmacies, which compound for individual patients with a valid prescription from a licensed provider, continue to operate legally.
The FDA proposed excluding GLP-1 medications from the 503B Bulk Substances List on April 30, 2026, but this proposal is still in the public comment period and has not become a final rule as of May 2026.
Yes, through licensed programs that use 503A pharmacies with valid provider prescriptions. As of May 2026, compounded semaglutide is available through CareBox, which works with state-licensed 503A pharmacies and requires a licensed provider prescription.
Yes, licensed healthcare providers can still write prescriptions for compounded semaglutide or compounded tirzepatide. 503A pharmacies can still fill those prescriptions. The legal framework that allows this (Section 503A of the Federal Food, Drug, and Cosmetic Act) has not changed.
Not through the licensed 503A pathway. What went away was large-scale bulk compounding from 503B outsourcing facilities, which was only authorized during the drug shortage period, from early 2022 until resolved in 2025. Licensed 503A compounding—patient-specific, provider-prescribed—remains legal.
CareBox is a national telehealth weight loss program offering compounded semaglutide and compounded tirzepatide through licensed healthcare providers and state-licensed 503A pharmacies.
When you join, you get:
Compounded GLP-1 medication is not appropriate for everyone. A licensed provider evaluation will review if:
If FDA news is raising questions about your compounded GLP-1 medication, bring these questions to your provider:
Your licensed healthcare provider is your most accurate, current source of information.
For full safety details, always review our Important Safety Information page.
Compounded GLP-1 medication is still available through CareBox. Start your consultation today—no insurance needed.
The FDA's 2024–2026 actions ended large-scale bulk compounding from outsourcing facilities. They also took action against unlicensed sellers and dangerous products.
They did not eliminate licensed medical compounding through 503A pharmacies, nor did they stop licensed healthcare providers from prescribing compounded GLP-1 medication for individual patients.
Important Safety Information
CareBox connects patients with licensed providers who may prescribe medication through state-licensed pharmacies. Prescription medication is only available if prescribed after an online consultation, as applicable, with a healthcare provider. Physicians may prescribe compounded medications as needed to meet medical necessity or drug shortages. The FDA does not review or approve any compounded medications for safety or effectiveness. Results may vary. Please review the Important Safety Information.
